Cargando…

Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

Resistance mechanisms and heterogeneity in HER2-positive gastric cancers (GC) limit Trastuzumab benefit in 32% of patients, and other targeted therapies have failed in clinical trials. Using patient samples, patient-derived xenografts (PDXs), partially humanized biological models, and HER2-targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Patrícia M. R., Mandleywala, Komal, Monette, Sébastien, Lumish, Melissa, Tully, Kathryn M., Panikar, Sandeep Surendra, Cornejo, Mike, Mauguen, Audrey, Ragupathi, Ashwin, Keltee, Nai C., Mattar, Marissa, Janjigian, Yelena Y., Lewis, Jason S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085816/ https://www.ncbi.nlm.nih.gov/pubmed/35534471 http://dx.doi.org/10.1038/s41467-022-30142-9

Ejemplares similares

Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
por: Pereira, Patrícia M.R., et al.
Publicado: (2019)

In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment
por: Panikar, Sandeep Surendra, et al.
Publicado: (2023)

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
por: Pereira, Patrícia M. R., et al.
Publicado: (2018)

PET and Optical Imaging of Caveolin-1 in Gastric Tumors
por: Surendra Panikar, Sandeep, et al.
Publicado: (2023)

Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers
por: Rao, Yi, et al.
Publicado: (2023)

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma
por: Cardenas, Fiorella Iglesias, et al.
Publicado: (2021)

Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications
por: Banu, Nehla, et al.
Publicado: (2020)

Antibody-Targeted Imaging of Gastric Cancer
por: Mandleywala, Komal, et al.
Publicado: (2020)

Molecular architecture of the human caveolin-1 complex
por: Porta, Jason C., et al.
Publicado: (2022)

Targeting EGFR in Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2020)

The caveolin proteins
por: Williams, Terence M, et al.
Publicado: (2004)

Caveolins in rhabdomyosarcoma
por: Rossi, Stefania, et al.
Publicado: (2011)

(89)Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma
por: Poty, Sophie, et al.
Publicado: (2020)

Caveolin-2 associates with intracellular chlamydial inclusions independently of caveolin-1
por: Webley, Wilmore C, et al.
Publicado: (2004)

Caveolin-1 and Caveolin-2 Can Be Antagonistic Partners in Inflammation and Beyond
por: de Almeida, Cecília Jacques Gonçalves
Publicado: (2017)

The liver that caveolin built
por: Wells, William A.
Publicado: (2006)

Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles
Publicado: (1994)

Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands
por: van Maaren, Marissa C., et al.
Publicado: (2022)

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases
por: Gerstenberger, Wladimir, et al.
Publicado: (2018)

Caveolin, Cholesterol, and Lipid Droplets?
por: van Meer, Gerrit
Publicado: (2001)

Caveolin-1 says NO to permeability
por: Leslie, Mitch
Publicado: (2011)

Integrin regulation of caveolin function
por: Salanueva, Iñigo J, et al.
Publicado: (2007)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Insulin stimulates the tyrosine phosphorylation of caveolin
Publicado: (1995)

Distribution of caveolin isoforms in the lemur retina
por: Berta, Ágnes I, et al.
Publicado: (2007)

Caveolin-1 in sarcomas: friend or foe?
por: Sáinz-Jaspeado, Miguel, et al.
Publicado: (2011)

Caveolin-1 Signaling in Lung Fibrosis
por: Tourkina, Elena, et al.
Publicado: (2012)

Revisiting caveolin trafficking: the end of the caveosome
por: Parton, Robert G., et al.
Publicado: (2010)

Caveolin-1 is an aggresome-inducing protein
por: Tiwari, Ajit, et al.
Publicado: (2016)

Caveolin as a Universal Target in Dermatology
por: Kruglikov, Ilja L., et al.
Publicado: (2019)

The structure of caveolin finally takes shape
por: Parton, Robert G., et al.
Publicado: (2022)

Involvement of caveolin-1 in skin diseases
por: Takamura, Naoko, et al.
Publicado: (2022)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
por: Ragupathi, Ashwin, et al.
Publicado: (2023)

Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice
por: Murata, Takahisa, et al.
Publicado: (2007)

Molecular Characterization of Caveolin Association with the Golgi Complex: Identification of a Cis-Golgi Targeting Domain in the Caveolin Molecule
por: Luetterforst, Robert, et al.
Publicado: (1999)

Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer
por: Sagara, Y, et al.
Publicado: (2004)

Caveolin-1 Expression and Hemodynamics in COPD Patients
por: Huber, Lars C, et al.
Publicado: (2009)

Caveolin-1-dependent and -independent membrane domains
por: Le Lay, Soazig, et al.
Publicado: (2009)

Caveolin-1, cellular senescence and pulmonary emphysema
por: Volonte, Daniela, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ue8toc7qd2vea1of8kgag4o8a3